anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a hydrophobic drug, namely a succinobucol nanosuspension and a preparation method thereof. The succinobucol nanosuspension, a nano composition, is a opalescent solution which is prepared from succinobucol, a surfactant and an aqueous phase according to a certain proportion. The succinobucol nanosuspension contains 1 part of the succinobucol and 0.1-1000 parts of the surfactant. The succinobucol nanosuspension is prepared through a filming-rehydration method, and a spray drying technology or a grinding technology, and the grain size of the prepared succinobucol nanosuspension is 10-200nm. The succinobucol nanosuspension can cause a drug to be easily absorbed to the body and is beneficial to improving the bioavailability of the drug. Compared with the succinobucol suspension, the succinobucol nanosuspension has the advantages that the in-vivo bioavailability of rats is improved by 10-44 times, and the curative functions of the succinobucol nanosuspension can be fully preformed.
This is a phase 2, randomized, double-blind study comparing SR750 with placebo in patients with trigeminal neuralgia. It consists of a screening period, a double-blind treatment period, and a post-treatment safety follow-up period. Baseline pain intensity and number of paroxysms will be taken in the run-in period of screening period and will be checked for eligibility. Around 162 eligible subjects will be recruited and randomized into three arms at 1:1:1 ratio to receive SR750 high dose twice a day (BID) , SR750 low dose BID or placebo BID for 6 weeks. Subjects, investigators, all clinical study site staffs, and the Sponsor will remain blinded to treatment assignment during the study. Subjects will be asked to record the number of paroxysms of pain, severity of daily average pain of paroxysms and severity of daily worst pain in e-diary over the last 24 hours every night before going to bed. After completion of double-blind period, subjects will continue to complete the safety follow-up.
A Randomized Clinical Trial will be conducted at Tehsil Head Quarter Hospital Daska through consecutive sampling technique on 42 patients which will be allocated using computer generated sampling (random number table) into Group A and Group B. Group A will be treated with Postisometric relaxation technique and Group B will be treated with Static stretching technique. Postisometric relaxation will be performed with the frequency of 5 times, such that it includes (30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold. Stretching exercise will be performed with 30 second hold and with 5 repetitions. All Exercises will be performed 3 times per week for total of 4 weeks. Outcome measures will be conducted through pain, range of motion, disability and muscle length after 4 weeks. Data will be analyzed during SPSS software version 25. The normality of data will be assessed by Shapiro-wilk test after which it will be decided either parametric or non-parametric test will be used within a group or between two groups.
A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients. A hydrophilic polymer, such as hydroxypropyl methylcellulose (HPMC E15), polyvinyl alcohol (PVA), or poloxamer, and/or a surfactant, such as sodium lauryl sulfate (SLS), can be included in the composition. A process for preparing the extrudate is conducted at a temperature approximating or above the softening or melting temperature of the matrix and below the point of solubilization of drug-containing particles in the carrier system, and below the recrystallization point in the case of amorphous fine drug particles.
The invention discloses an azobenzene-mediated hypoxia response type antibody crosslinking product and a composition containing the same, and the azobenzene-mediated hypoxia response type antibody crosslinking product is called H103-azo-PEG for short  5000  Wherein H103 is shorthand for H103 monoclonal antibody; the amino acid sequence of the heavy chain variable region of the H103 monoclonal antibody is shown as SEQ ID NO. 1; the amino acid sequence of the light chain variable region of the H103 monoclonal antibody is shown as SEQ ID NO. 2. The antibody cross-linked product of the invention can effectively prolong the half-life of the antibody, improve the bioavailability, and in addition, can effectively reduce the nonspecific cross-binding of the antibody with the antigen of non-tumor cells, thereby eliminating the cross-off-target effect of the antibody, reducing the toxic and side effects to the greatest extent, andand the clinical treatment effect is synergistically improved. The composition containing the azobenzene-mediated hypoxia response type antibody cross-linked compound has the advantage that the curative effect is fully verified in a liver cancer-bearing mouse model. Is beneficial to developing a series of safer and more effective similar medicaments and promotes the application of the medicaments to clinical practice of accurate tumor treatment.
A system and method for stabilizing a position of an object are disclosed. The system comprises a housing that includes a subsystem. The system also includes an attachment arm coupled to the housing. At least one first sensor is placed along the attachment arm, wherein the attachment arm is configured to receive the object thereto. In response to an unintentional muscle movement by a user that adversely affects the motion of the object, the subsystem stabilizes the position of the object. The method comprises providing a subsystem within a housing and coupling an attachment arm to the housing. The method also includes placing at least one first sensor along the attachment arm, wherein the attachment arm is configured to receive the object thereto. In response to an unintentional muscle movement by a user that adversely affects the motion of the object, the subsystem stabilizes the position of the object.
Information regarding reversal of unfractionated heparin (UFH) with protamine sulfate (PS) is based on expert consensus from 2012, which recommends use of UFH in order to achieve activated clotting time (ACT) \> 300 seconds as well as UFH reversal with PS in case of TAVI via transapical access as well as transfemoral access with the exception of cases with minimal bleeding risk. However, the clinical practice varies between centers - some use PS routinely, others - only in selected cases. The actual impact of PS on bleeding complications reduction is unknown. Furthermore, a pro-thromboembolic effect of the PS cannot be excluded. Both bleeding (major and life-threatening according to Valve Academic Research Consortium \[VARC\] criteria) and thromboembolic complications increase mortality after TAVI. The occurrence of these complications in international TAVI registries in 30-day observation ranges from 9.7% in case of major bleeding, 4.7% in case of life-threatening bleeds and 5% in case of strokes. There are no randomized studies assessing impact of PS on frequency of bleeding and thromboembolic complications after TAVI, its side-effects and influence on mortality. Randomized trial is required in order to assess impact of protamine sulfate on prevalence of bleeding and thromboembolic complications.
Gestational diabetes mellitus (GDM) is the onset of carbohydrate intolerance that affects up to 6-9% of pregnancies. A diagnosis of GDM conveys numerous implications for the health of the mother and the fetus if not properly identified and/or treated. Maternal complications include increased risk of preeclampsia and development of Type 2 diabetes mellitus later in life. The risks to the fetus include increased risk of macrosomia, stillbirth, hypoglycemia, shoulder dystocia as well as increased risk of childhood obesity and diabetes.

Per ACOG guidelines, women who are at an increased risk for undiagnosed pre-gestational diabetes mellitus or developing GDM should receive early screening when they initially present for prenatal care, most commonly in the late first or early second trimester.5 The best test for this early assessment is not yet established. Practices patterns vary between use of the two-step oral glucose tolerance screening and glycated hemoglobin (HbA1c). Use of the oral glucose tolerance tests for screening of GDM is well-established and the cut-offs determined for 24-28 week routine screening are used when the oral tolerance tests are administered in early pregnancy. An HbA1c level ≥6.5% is used to diagnose diabetes, however there is evidence that there is a higher rate of GDM diagnosis and poor outcomes with a HbA1c level as low as 5.6%. Women who are not diagnosed with GDM before 20 weeks, go on to routine screening at 24-28 weeks.

With the current protocols for early GDM screening, treatment of early glucose intolerance has not shown to improve neonatal outcomes, however. The methods and timing of current early GDM screening may not be identifying a population that is truly at risk of poor outcomes from glucose intolerance in the way routine screening with the two-step process does. More research into screening paradigms other than oral tolerance tests in early pregnancy is needed. A HbA1c level assesses the amount glycation of hemoglobin molecules in red blood cells, indirectly estimating the average blood glucose level over the past 8-12 weeks. HbA1c independently has not been shown to be adequately predictive of a GDM diagnosis in pregnancy. Many studies assessing the screening value of HbA1c obtain the value in the first trimester when a large portion of the 12 weeks prior is before significant placentation. A change in HbA1c in the first half of pregnancy, when combined with other clinical variables may be more predictive. Novel clinical variables should also be considered. There is evidence that even well-control pre-gestational and gestational diabetics show significant variation in fetal cardiac functional parameters such as interventricular septum thickness (IVS), the E/A ratio, and myocardial performance index (MPI). The predictive value of these changes for glucose intolerance has not yet been investigated.

This is be a prospective cohort study to assess the predictive value of fetal cardiac parameters, the change in fetal cardiac parameters (CFP), HbA1c, and/or the change in HbA1c (ΔHbA1c) for gestational diabetes.
The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
A randomized controlled trial design will be used to evaluate an empowerment-based program.. From August 2019 to July 2021, 160 subjects will be recruited at a medical center and randomly assigned to the intervention or comparison group. Participants in the intervention group will receive an assessment of their self-care demand and self-efficacy, as well as an empowerment-based program delivered by the project host. The program includes the identification of the problems of participants, clarification of their feelings and the significance of their problems, plan setting discussion, motivation for action, and evaluation of the execution of their plan. Empowerment-based strategies will be provided individually at the following time points: before discharge, on post-discharge days 3, 7, 14, 21, 28, 42, 56, 70, and 84, and at 6, 9, and 12 months post-discharge. Those in the comparison group will receive routine care only. Outcome measures include self-care behaviors, glycemic control (measured by HbA1C), diabetic foot ulcer infection, and diabetic foot ulcer recurrence. Data will be collected at baseline and at 1, 3, 6, and 12 months after discharge
Patients receive venetoclax orally PO QD on days 1-7 or 1-14 and azacitidine SC or IV over 15 minutes on days 1-5. Cycles repeat every 4-8 weeks in the absence of disease progression or unacceptable toxicity.
The invention discloses a black fungus polysaccharide and grape pip procyanidine composite antioxidant capsule, and relates to an antioxidant product. The black fungus polysaccharide and grape pip procyanidine composite antioxidant capsule is prepared by mixing 100g of starch and 6-12g of black fungus polysaccharide extract and grape pip procyanidine composition, wherein the black fungus polysaccharide extract and grape pip procyanidine composition is prepared from 40-60 parts by weight of black fungus polysaccharide extract and 40-60 parts by weight of procyanidine extract. The preparation method comprises the following steps of: firstly, selecting materials and weighing; then, extracting effective active components; mixing the extract with starch to prepare powder; and finally, packaging according to different specifications. The capsule is simple in production process. In vitro experiments show that the composite capsules have the adding, synergistic interaction and antioxidant effect. The capsules have the characteristics of convenience in administration in form and quick and complete absorption, so that the capsules are suitable for all crowds to take, and have wide market prospect.
The invention provides a target sequence of RNA virus, which is a nucleic acid sequence fragment containing 20-40 bases in an RNA virus gene sequence and having similarity of not less than 95% with a human genome sequence or related species such as livestock and poultry; the target sequence of the RNA virus is selected from SEQ ID NO. 1-SEQ ID NO. 615. The invention also relates to a primer composition for constructing the target sequence, biological materials such as antisense RNA and the like related to the target sequence, and related applications such as vaccine design for deleting the target sequence. The virus fragment of the sequence constructed by the invention has the function of interacting with human genome DNA, is similar to virus miRNA, simultaneously verifies the influence of an over-expressed RNA virus target sequence on the expression level of peripheral genes, and provides a brand new concept that the target fragment is an important pathogenic substance of the RNA virus. The target sequence has important application values in the detection and diagnosis of RNA viruses, drug screening, treatment of diseases caused by the RNA viruses and vaccine design/optimization methods.
All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
The present invention discloses a cold-dispelling pus-drawing-out stasis-resolving plaster which belongs to the technical field of traditional Chinese medicine. According to the formula of traditional Chinese medicine theory, the drug effects of various drugs are exerted. The functions of cold dispelling, pus drawing-out, stasis resolving, anti-inflammation and analgesia are generated for the human body. The plaster of the invention is prepared by the following components: areca catechu, angelica sinensis, radix aconiti Kusnezoffi, chuanxiong rhizome, ledebouriella root, angelia, clematis chinensis, safflower, cynanchum paniculatum, sappanwood, tuberculate speranskia herb, frank incense, buck grass, radix achyranthis bidentatae, homalomena occulta, dragon's blood, minium and fragrant sesame oil. The frank incense and dragon's blood are processed to the powder with 120 meshes for standby. The minium is used for standby. The fragrant sesame oil is placed in an iron pan. Then the rest traditional Chinese medicines are placed into the iron pan for soaking for 2 days. Then the firewood is ignited for decocting. The filtering is executed and the medicine oil is decocted. The minium is placed and is mixed to uniform with a wood stick. The medicine is continuously decocted until a state when the medical ointment drawn by the wood stick has a wire shape. The frank incense and dragon's blood which are processed to the powder with 120 meshes are placed into the medical ointment and mixed to uniform. Then the medical ointment is placed into the cold water for cooling. The cooled medical ointment is divided into the small blocks with the weight of each block for 5 grams. The talc powder is used for preventing the blocking between blocks. The prepared cold-dispelling pus-drawing-out stasis-resolving plaster is sealed for standby.
The compositions of the present invention relate to improved aqueous or aqueous-alcoholic hair styling compositions comprising a combination of two copolymers. The first copolymer is a copolymer of (a1) acidic vinyl monomers, e.g. acrylic or methacrylic acid, with (a2) hydrophobic nonionic vinyl monomers, e.g. acrylic or methacrylic acid esters, with (a3) a first associative monomer and (a4) at least one other monomer which can be a second associative monomer different from the first associative monomer or a semihydrophobic monomer. The associative monomers having (i) an ethylenically unsaturated end group, (ii) a hydrophilic midsection and (iii) a hydrophobic or semi-hydrophobic end group. The second copolymer is a copolymer of (b1) C3 to C8 monoethylenically unsaturated monocarboxylic acid monomers, (b2) acrylic or methacrylic acid alkyl esters, and (b3) acrylic or methacrylic acid hydroxyalkyl esters. Preferred product forms are gels, additionally containing a gel forming agent. Thecompositions can be used for increasing the humidity resistance, moisture resistance or sweat resistance of a hair style.
For several years, we have been applying the concept of Enhanced Recovery Program (ERP) for colorectal surgery at CHU Liége (Belgium). Since October 2015, the University Hospital of Liège has been labelled as reference center for ERP after colorectal surgery by a French-speaking organization GRACE (French-speaking group for Enhanced Recovery after Surgery; www.grace-asso.fr). Despite the benefits for the patient and the economic benefits of such programs, some criticize ERP arguing that patients are asked to return home too early, while they have not recovered a satisfactory autonomy. Few studies have investigated the comfort and quality of home life of patients who have had ERP. We recently conducted a retrospective study to evaluate this quality of life. It turns out that patients report little postoperative pain, a sufficient degree of autonomy at home, and a high general satisfaction score (\> 8.5 on a numerical scale of 0 to 10). However dietary and digestive difficulties were described by about one third of the patients questioned. \[6\] Others have also reported a caloric-protein deficit during the immediate postoperative period after colorectal surgery, up to the 7th day in some of their patients \[7\].

Aim of the study. The aim of this study is to assess caloric-protein intake up to one month after colorectal surgery within ERP.

General description. This observational study will quantify caloric-protein intake in 75 patients undergoing colorectal surgery according to an ERP at CHU Liège. A dietary survey will be performed preoperatively and repeated postoperatively via telephone calls on Day + 3, Day + 7; Day + 15, and Day + 30, after leaving the hospital. The deficits observed will be correlated with the medical and surgical characteristics of the patients.
Patients receive cediranib maleate PO QD on day 1. Patients undergoing FMISO scan also receive olaparib PO BID beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of cycle 1. Cycles repeat every 28 days (35 days for cycle 1) in the absence of disease progression or unacceptable toxicity.
Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
INTRODUCTION: Coronary cameral fistulas (CCFs) are rare congenital anomalies characterized by abnormal connections between a coronary artery and one of the cardiac chambers. These abnormal connections can lead to significant clinical implications, including heart failure and myocardial ischemia, necessitating timely diagnosis and intervention.
CASE PRESENTATION: A 5-year-old Iranian boy was brought to the emergency room at Heart Hospital Center complaining of chest pain and dyspnea on exertion. He had experienced similar episodes over the past 4 months, which had not been evaluated. Physical examination revealed stable vital signs and no remarkable findings. Transthoracic echocardiography demonstrated a dilated left coronary artery with a large aneurysm and a small orifice to the right ventricular body. The left ventricular ejection fraction was 55%. Cardiac computed tomography angiography confirmed the diagnosis. Cardiac angiography showed a dilated left coronary artery and a coronary cameral fistula to the right ventricular . The aneurysm was successfully occluded using two Amplatzer™ devices.
CONCLUSION: This case underscores the critical role of multimodal imaging in diagnosing and managing coronary cameral fistulae. Early detection and appropriate intervention are paramount in preventing the progression of symptoms and potential complications such as heart failure and myocardial ischemia. The successful closure with Amplatzer™ devices highlights the efficacy of minimally invasive techniques in treating complex cardiovascular anomalies. Regular follow-up and careful monitoring are essential to ensure long-term success and to manage any potential recurrences.
CLINICAL KEY MESSAGE: Timely identification and management of coronary cameral fistulae are crucial to prevent complications. Advances in imaging techniques and minimally invasive treatments, such as transcatheter closure, offer effective solutions. A multidisciplinary approach and regular follow-up are essential for comprehensive care and successful long-term management.